Puma shares ripped after growing grade 3 diarrhea threat is highlighted in an abstract
The skeptics ripped into Puma Biotechnology $PBYI today, tearing a 20% chunk out of its share price by early afternoon on Monday after getting a glimpse of its lead cancer drug’s continuing problems spurring severe cases of diarrhea in patients.
The reaction quickly set in after Puma posted an abstract for an upcoming cancer symposium which spelled out the increasing rates in neratinib trials. RBC’s Simos Simeonidis sat down to compare the numbers, and reached a few unsettling conclusions. Here’s a note he posted Monday afternoon:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.